icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Articles /

Biophytis Unveils Ambitious 2025 Roadmap: Expanding Therapeutic Pipeline and Global Presence

Marcus LeeTuesday, Feb 11, 2025 1:10 am ET
3min read


Biophytis SA, a clinical-stage biotechnology company specializing in age-related diseases, has outlined its strategic roadmap for 2025, focusing on expanding its therapeutic pipeline and global presence. The company, headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil, is poised to accelerate the clinical development and commercialization of its lead drug candidate, BIO101 (20-Hydroxyecdysone), through a series of strategic initiatives.



Biophytis' 2025 roadmap includes several key developments aimed at expanding its therapeutic pipeline and addressing major medical needs. The company plans to launch the OBA clinical development program for the treatment of obesity, targeting a rapidly expanding market estimated to reach $100 billion by 2030. This initiative, in collaboration with Blanver and other potential partners, will evaluate the efficacy of BIO101 (20-Hydroxyecdysone) in obese patients treated with GLP-1 RAs and following a hypocaloric diet. Additionally, Biophytis has signed a co-development agreement with AskHelpU in ALS, exploring the potential of BIO101 in a new indication and further diversifying its therapeutic pipeline.



Biophytis' strategic roadmap also emphasizes strengthening its global presence and impact across key geographies. The company has entered exclusive negotiations with a major Chinese pharmaceutical company to license BIO101, expanding its reach in the Asian market. Furthermore, Biophytis has concluded a co-development agreement with AskHelpU in ALS, enabling the company to address crucial public health issues in multiple regions and consolidate its growth and impact.



Biophytis plans to launch phase 3 of its SARA clinical program in the coming months, aimed at confirming the efficacy of BIO101 (20-Hydroxyecdysone) in sarcopenia. This indication represents a major unresolved public health issue, with a rapidly expanding market representing some 30 million patients in China and a growing prevalence in Europe and the United States. By accelerating the clinical development and commercialization of BIO101, Biophytis aims to bring therapeutic solutions to patients in need while consolidating its growth and impact across all key geographies.

opening price(6527)
market cap(6527)
opening price;market cap(6527)
Opening Price(USD)2025.02.10
Market Cap(USD)2025.02.10
711.32K1010.29B
8K 25.19B
4.96K 163.06B
3.43K 54.18B
2.53K 2.87B
2.22K 30.03B
2.03K 93.08B
2.02K 22.69B
1.94K 4.76B
2K 46.41B
Ticker
BRK.ABerkshire Hathaway A
NVRNVR
BKNGBooking Holdings
AZOAutozone
SEBSeaboard
FCNCAFirst Citizens Bancshares
MELIMercadolibre
MKLMarkel Group
WTMWhite Mountains Insurance Group
FICOFair Isaac
View 6527 resultsmore


In conclusion, Biophytis' strategic roadmap for 2025 aligns with its long-term vision for growth and impact in key geographies. By expanding its therapeutic pipeline, strengthening its global presence, and accelerating the clinical development and commercialization of BIO101, Biophytis is well-positioned to address major medical needs and consolidate its growth and impact across all key geographies. As the company continues to execute its roadmap, investors should monitor its progress and consider the potential opportunities and risks associated with its ambitious plans.
Comments

Add a public comment...
Post
User avatar and name identifying the post author
Smith Bernard
02/11

Catherine E. Russell is a beacon of innovation and positivity in the world of cryptocurrency and investments. Her dedication to building a transformative Bitcoin and crypto platform has touched the lives of people around the globe. Catherine passion for empowering individuals to navigate the exciting world of digital assets is truly inspiring. Through her platform, she is creating opportunities, spreading knowledge, and fostering a community of like-minded individuals all striving for financial empowerment. Catherine vision and drive are shaping the future of finance, and her impact is felt far and wide. Let's celebrate Catherine E. Russell for her incredible work and commitment to making the world of cryptocurrency accessible to all.Massage✍️ On FACEBOOK  Catherine E. Russell   .. It is important to be informed an make informed decisions

0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App